Application Detail
Status
ClosedDescription of Medical Service
ImmunoHistoChemistry test for evaluation of Programmed Cell Death Ligand 1 (PD-L1) expression to determine eligibility for treatment with pembrolizumabDescription of Medical Condition
Locally advanced or metastatic non-small cell lung cancerReason for Application
New MBS itemMedical Service Type
InvestigativePrevious Application Number
1440Associated Documentation
Application Form
-Consultation Survey
-PICO Confirmation
see Application 1440Assessment Report
-Public Summary Document
Public Summary Document (PDF 314 KB)Public Summary Document (Word 105 KB)
Meetings for this Application
PASC
-ESC
-MSAC
23 November 201728-29 March 2018
26-27 July 2018